Rapport Therapeutics (RAPP) Operating Leases (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Operating Leases of $8.2 million for Q1 2026, up 19.81% year-over-year from $6.8 million in Q1 2025, and down 6.2% quarter-over-quarter from $8.7 million in Q4 2025.
Rapport Therapeutics (RAPP) Operating Leases (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Operating Leases for 4 consecutive years, with $8.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 19.81% year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $8.2 million (up 19.81% YoY), while the FY2025 annual figure was $8.7 million, up 1081.19% from the prior year.
- Operating Leases slipped to $8.2 million in Q1 2026 per RAPP's latest filing, from $8.7 million in the prior quarter.
- Across five years, Operating Leases topped out at $10.1 million in Q2 2025 and bottomed at $739000.0 in Q4 2024.
- Historically, Operating Leases has averaged $5.3 million across 4 years, with a median of $6.8 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Leases plunged 49.93% — and 2025, when it surged 1081.19%.
- Rapport Therapeutics' Operating Leases stood at $1.5 million in 2023, then slumped by 49.93% to $739000.0 in 2024, then soared by 1081.19% to $8.7 million in 2025, then retreated by 6.2% to $8.2 million in 2026.
- Business Quant data shows RAPP's Operating Leases at $8.2 million in Q1 2026, $8.7 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.63 Mn |
| Mar 31, 2026 | 8.19 Mn |
| Dec 31, 2025 | 8.73 Mn |
| Sep 30, 2025 | 9.39 Mn |
| Jun 30, 2025 | 10.10 Mn |
| Mar 31, 2025 | 6.83 Mn |
| Dec 31, 2024 | 739,000.00 |
| Sep 30, 2024 | 931,000.00 |
| Jun 30, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.48 Mn |